GENE - CHEMICAL INTERACTIONS REPORT
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
Object Symbol | Qualifier | Evidence | With | Reference | Source | Notes | Original Reference(s) | Pparg | increases expression | ISO | Pparg (Mus musculus) | 6480464 | CTD | Rifampin results in increased expression of PPARG mRNA | PMID:27806127 | Pparg | multiple interactions | ISO | Pparg (Mus musculus) | 6480464 | CTD | [Isoniazid co-treated with Rifampin] results in decreased expression of PPARG protein; [Rifampin affects the susceptibility to Dietary Fats] which results in decreased expression of PPARG mRNA; [Rifampin affects the susceptibility to Dietary Fats] which results in decreased expression of PPARG mRNA alternative form; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG mRNA alternative form]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG protein]; Rifampin results in increased expression of and affects the localization of PPARG protein | PMID:27806127 PMID:33412187 PMID:36347327 | |
Go Back to source page | Continue to Ontology report |